Tag Archive for: Cancer

Poolbeg Pharma plc – Notice of Allowance received for POLB 001 Cancer Immunotherapy-induced CRS patent in Israel

/in

Continued momentum in Poolbeg’s global intellectual property strategy 21 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received a Notice of Allowance for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from the Israeli Patent […]

Read more

Poolbeg Pharma Plc – Placing to raise £3.5 million, Executive Chair Cathal Friel subscribes for £250,000

/in

Poolbeg Pharma Plc (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, is pleased to announce that it has raised £3.5 million (before expenses) pursuant to a placing of 58,333,328 new ordinary shares of 0.02 pence each in the capital of the Company (“Placing Shares”) with certain existing institutional and other investors (“Placing”). […]

Read more

Poolbeg Pharma plc – First Patient Dosed in the POLB 001 TOPICAL Clinical Trial

/in

Interim data remains on track for summer 2026 and partnering discussions continue to advance with multiple companies Highlights ·    First patient dosed in the POLB 001 TOPICAL clinical trial ·    Second site, University College London Hospital, activated with patient recruitment underway ·    Additional clinical sites expected to open imminently, supporting continued patient recruitment 13 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or […]

Read more

Poolbeg Pharma plc – POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza

/in

Patent decision strengthens Poolbeg’s intellectual property portfolio 30 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces it has received notification of the official decision to grant Poolbeg’s Immunomodulator II patent in South Africa, providing protection for POLB 001 for the prevention of hypercytokinaemia and […]

Read more

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

/in

Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025 Oslo, Norway, 18 June 2026: Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of […]

Read more
© Optimum Strategic Communications.